INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2009

Oral curcumin reduced paraprotein load in half of patients with baseline paraprotein levels over 20 g/L and decreased a bone turnover marker in 27% of patients.

Twenty-six patients with monoclonal gammopathy of undefined significance (MGUS) were administered 4 grams/day of oral curcumin to examine its effects on plasma cells and osteoclasts. Among patients with a paraprotein level >20 g/L, 50% (5 of 10) experienced a 12% to 30% reduction in paraprotein levels during curcumin therapy. Additionally, 27% of patients on curcumin demonstrated a >25% decrease in the bone turnover marker urinary N-telopeptide of type I collagen.

Study type
Intervention trial
Who was studied
26 patients with MGUS
What was measured
Paraprotein load, urinary N-telopeptide of type I collagen, and other markers

THE PAPER

The potential role of curcumin in patients with monoclonal gammopathy of undefined significance--its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker.

Golombick T, Diamond TH, Badmaev V, Manoharan A, Ramakrishna R. Clin Cancer Res, 2009.

PubMed 19737963 ↗DOI 10.1158/1078-0432.ccr-08-2217 ↗

CancerBones & muscles

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.